Histone Demethylase Expression Enhances Human Somatic Cell Nuclear Transfer Efficiency and Promotes Derivation of Pluripotent Stem Cells

Highlights

- H3K9me3 is a barrier for human SCNT reprogramming as in mouse
- Injection of human KDM4A mRNA improves SCNT success in mouse oocytes
- KDM4A also improves human SCNT blastocyst formation and NT-ESC derivation
- H3K9me3 removal facilitates zygotic genome activation in human SCNT embryos

Authors

Young Gie Chung, Shogo Matoba, Yuting Liu, ..., Kwang Yul Cha, Dong Ryul Lee, Yi Zhang

Correspondence
drleedr@cha.ac.kr (D.R.L.), yzhang@genetics.med.harvard.edu (Y.Z.)

In Brief

Zhang and colleagues show that, as they found previously in mouse, injection of a histone demethylase improves the efficiency of human SCNT reprogramming. Using this approach they were able to reduce variability in success from different egg donors and derive human NT-ESC lines from patients with age-related macular degeneration.

Accession Numbers

GSE73362
Histone Demethylase Expression Enhances Human Somatic Cell Nuclear Transfer Efficiency and Promotes Derivation of Pluripotent Stem Cells

Young Gie Chung,1,2,7 Shogo Matoba,3,4,5,7,8 Yuting Liu,3,4,5 Jin Hee Eum,2 Falong Lu,3,4,5 Wei Jiang,3,4,5,9 Jeoung Eun Lee,2 Vicken Sepilian,1 Kwang Yul Cha,2 Dong Ryul Lee,1,2,* and Yi Zhang3,4,5,6,*

1Research Institute for Stem Cell Research, CHA Health Systems, Los Angeles, CA 90036, USA
2CHA Stem Cell Institute, CHA University, Seoul 135-081, Korea
3Howard Hughes Medical Institute
4Program in Cellular and Molecular Medicine, Boston Children’s Hospital
5Department of Genetics
6Harvard Stem Cell Institute
Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA
7Co-first author
8Present address: RIKEN Bioresource Center, Tsukuba, Ibaraki 305-0074, Japan
9Present address: Medical Research Institute and Zhongnan Hospital, Wuhan University, Wuhan 430071, China
*Correspondence: drleedr@cha.ac.kr (D.R.L.), yzhang@genetics.med.harvard.edu (Y.Z.)

http://dx.doi.org/10.1016/j.stem.2015.10.001

SUMMARY

The extremely low efficiency of human embryonic stem cell (hESC) derivation using somatic cell nuclear transfer (SCNT) limits its potential application. Blastocyst formation from human SCNT embryos occurs at a low rate and with only some oocyte donors. We previously showed in mice that reduction of histone H3 lysine 9 trimethylation (H3K9me3) through ectopic expression of the H3K9me3 demethylase Kdm4d greatly improves SCNT embryo development. Here we show that overexpression of a related H3K9me3 demethylase KDM4A improves human SCNT, and that, as in mice, H3K9me3 in the human somatic cell genome is an SCNT reprogramming barrier. Overexpression of KDM4A significantly improves the blastocyst formation rate in human SCNT embryos by facilitating transcriptional reprogramming, allowing efficient derivation of SCNT-derived ESCs using adult Age-related Macular Degeneration (AMD) patient somatic nuclei donors. This conserved mechanistic insight has potential applications for improving SCNT in a variety of contexts, including regenerative medicine.

INTRODUCTION

The differentiated somatic cell genome can be reprogrammed back into an embryonic state when the nucleus is exposed to the molecular milieu of the oocyte cytoplasm via somatic cell nuclear transfer (SCNT) (Gurdon, 1962), thereby enabling the generation of pluripotent embryonic stem cells (ESCs) from terminally differentiated somatic cells (Wakayama et al., 2001). Because SCNT-derived ESCs (NT-ESCs) are genetically autologous to the nuclear donor somatic cells, SCNT has great potential in therapeutic and regenerative medicine, including disease modeling and cell/tissue replacement therapy (Hochedlinger and Jaenisch, 2003; Yang et al., 2007). Thus, SCNT can be used to fix mitochondria-gene-related defects, which cannot be done through transcription-factor-based reprogramming (Ma et al., 2015). Despite the great potential of human NT-ESCs, technical difficulties makes its application to human therapeutics extremely difficult (French et al., 2008; Noggle et al., 2011; Simerly et al., 2003).

The first NT-ESCs were generated by the Mitalipov group using differentiated fetal and infant fibroblasts as nuclear donors (Tachibana et al., 2013). Using their optimized conditions, we and others succeeded in deriving human NT-ESCs from adult and aged patient somatic cells (Chung et al., 2014; Yamada et al., 2014). However, derivation of NT-ESCs still remains a very difficult task due to the extremely low rate of SCNT embryos developing to the blastocyst stage. Currently only oocytes with the highest quality from certain females can support the development of SCNT embryos to the blastocyst stage (Chung et al., 2014; Tachibana et al., 2013), limiting the useful oocyte donor pools.

The poor developmental potential of SCNT embryos is not limited to human; it is also commonly observed in all examined mammalian species (Rodriguez-Osorio et al., 2012). Through comparative transcriptomic and epigenomic analyses of mouse in vitro fertilization (IVF) and SCNT embryos, we have recently revealed that histone H3 lysine 9 trimethylation (H3K9me3) in the donor somatic cell genome functions as a barrier preventing transcriptional reprogramming by SCNT, leading to failure of zygotic genome activation (ZGA) and preimplantation development (Matoba et al., 2014). Importantly, we demonstrated that this epigenetic barrier could be removed by the ectopic overexpression of mouse Kdm4d, an H3K9me3 demethylase. Removal of H3K9me3 facilitates ZGA and consequently improves development of mouse SCNT embryos to reach the blastocyst stage, leading to an increased rate of mouse NT-ESC establishment.
Figure 1. Human RRRs Are Enriched for H3K9me3 in Somatic Cells
(A) Schematic illustration of the experimental procedures. Samples used for RNA-seq are marked by dashed rectangles.
(B) Heatmap illustration of the transcriptome of IVF human preimplantation embryos. Each tile represents an average of peaks within the region obtained by sliding-window analysis. Shown are the 707 regions that are activated from the four-cell to the eight-cell stage in IVF embryos. RNA-seq datasets were obtained from a previous publication (Xue et al., 2013).
(C) Heatmap illustration of the transcriptome comparing donor somatic cells, IVF embryos, and SCNT embryos at the eight-cell stage. Shown are the 707 regions identified in (A). These regions were classified into three groups based on the fold-change (FC) in transcription levels between SCNT and IVF eight-cell embryos. FRRs, PRRs, and RRRs indicate fully reprogrammed regions (FC ≥ 2), partially reprogrammed regions (2 < FC ≤ 5), and reprogramming-resistant regions (FC > 5), respectively.
(D) The average ChIP-seq intensity of H3K9me3 and H3K4me3 in human fibroblast cells (Nhlf) are shown within FRR, PRR, and RRR compared with 200 kb flanking regions. Histone modification ChIP-seq datasets were obtained from the ENCODE project (Bernstein et al., 2012; ENCODE Project Consortium, 2011).
Identification of Reprogramming-Resistant Regions in Eight-Cell Human SCNT Embryos

Human ZGA takes place during the late four-cell to the late eight-cell stages (Niakan et al., 2012) (Figure 1A). To identify the genomic regions activated during ZGA of normal human IVF embryos, we analyzed published human preimplantation embryo RNA-sequencing (RNA-seq) datasets (Xue et al., 2013) and identified 707 genomic regions ranging from 20 to 160 kb in size (Table S1) that were activated at least 5-fold at the eight-cell stage compared to the four-cell stage (Figure 1B).

To determine whether ZGA takes place properly in human SCNT, we collected late eight-cell stage embryos (five/group), derived either from SCNT or IVF, and performed RNA-seq (Figure 1A). In parallel, we also performed RNA-seq of the donor dermal fibroblast cells (DFB-8, see Experimental Procedures). Analysis of the 707 genomic regions defined above (Figure 1B, Table S1) indicates that the majority of the ZGA regions are activated in the SCNT embryos compared to those in donor fibroblasts (Figure 1C). However, the level of activation is not comparable to that in IVF embryos (Figure 1C). Of the 707 genomic regions, 169 were activated at a level comparable to those in IVF embryos (FC ≤ 2, IVF versus SCNT), and were thus termed fully reprogrammed regions (FRRs) following our previous definition (Matoba et al., 2014). Similarly, 220 regions were partially activated (2 < FC ≤ 5) in SCNT compared to IVF embryos and were termed partially reprogrammed regions (PRRs). However, the remaining 318 regions (Table S2), termed reprogramming-resistant regions (RRRs), failed to be activated in SCNT embryos (FC > 5). Thus, comparative transcriptome analysis allowed us to identify 318 RRRs that were refractory to transcriptional reprogramming in human eight-cell SCNT embryos.

The Heterochromatin Features of RRRs Are Conserved in Human Somatic Cells

We next asked whether the human RRRs possess the heterochromatin features like those of the mouse RRRs. Analysis of the publically available ChIP-seq datasets of eight major histone modifications from human fibroblast cells (Bernstein et al., 2012; ENCODE Project Consortium, 2011) revealed specific enrichment of H3K9me3 in human RRRs (Figures 1D and S1A). The enrichment of H3K9me3 is unique to RRRs, as a similar enrichment was not observed in FRRs or PRRs (Figures 1D and S1A). Similar analysis also revealed the enrichment of H3K9me3 at RRRs in K562 erythroleukemic cells, Hsmm skeletal muscle myoblasts, and Mcf7 breast adenocarcinoma cells (Figures 1E and S1B), indicating that H3K9me3 enrichment in RRRs is a common feature of somatic cells.

Next, we analyzed the DNase hypersensitivity of four different somatic cell types using the datasets generated by the ENCODE project. The analysis revealed that RRRs are significantly less sensitive to DNase compared to FRR and PRR in all human somatic cell types analyzed (Figures 1F and S1C). Consistent with their heterochromatin feature, human RRRs are relatively gene-poor compared to FRRs or PRRs (Figure S1D), and they are enriched with specific repeat sequences such as LINE and LTR, but not SINE (Figure S1E). Collectively, these results indicate that the heterochromatin features of RRRs, enrichment of H3K9me3, and decreased accessibility to DNase are conserved in both mouse and human somatic cells.

Human KDM4A mRNA Injection Improves Development of Mouse SCNT Embryos

Having established that human RRRs are enriched for H3K9me3, we next asked whether removal of H3K9me3 could help overcome the reprogramming barrier in human SCNT embryos. We previously demonstrated using a mouse SCNT model that the H3K9me3 barrier could be removed by injection of mRNAs encoding the mouse H3K9me3 demethylase Kdm4d (Matoba et al., 2014). Before moving into a human SCNT model, given that multiple members of the KDM4 family with H3K9me3 demethylase activity exist in mouse and human (Klose et al., 2006; Krishnan and Tri Evel, 2013; Whetstine et al., 2006), we were interested in determining whether the effect of Kdm4d in facilitating SCNT reprogramming could be extended to other members of the KDM4 family. In addition, we were also interested in testing whether KDM4 family members could function across species.

To this end, we performed SCNT using cumulus cells of adult female mice as nuclear donors and injected human KDM4A mRNA at 5 hr post-activation (hpa) following the same procedure used in our previous study (Figure 2A) (Matoba et al., 2014). Immunostaining revealed that injection of WT, but not catalytic mutant, human KDM4A mRNA greatly reduced H3K9me3 levels in the nucleus of mouse SCNT embryos (Figure 2B). Importantly, injection of KDM4A mRNA greatly increased the developmental potential of SCNT embryos with 90.3% of them developing to the blastocyst stage, which is in contrast to the 26% blastocyst formation rate in controls (Figures 2C and 2D, Table S3). The extremely high efficiency of blastocyst formation is similar to the 88.6% observed in Kdm4d-injected mouse SCNT embryos (Matoba et al., 2014). These results suggest that the
**MOUSE**

- 1 h SCNT activation mRNA injection blastocyst

**HUMAN**

- Dermal fibroblast of AMD patient SCNT by HVJ-E activation by electropulse and 6-DMAP Injection of KDM4A mRNA expanded blastocyst

**F**

<table>
<thead>
<tr>
<th>Developmental Rate</th>
<th>control (n=48)</th>
<th>KDM4A (n=56)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-cell</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>4-cell</td>
<td>87.5</td>
<td>89.3</td>
</tr>
<tr>
<td>8-cell</td>
<td>68.8</td>
<td>71.4</td>
</tr>
<tr>
<td>16.7</td>
<td>32.1</td>
<td>P&lt;0.02</td>
</tr>
<tr>
<td>4.2</td>
<td>26.8</td>
<td>P&lt;0.03</td>
</tr>
<tr>
<td>0</td>
<td>14.3</td>
<td></td>
</tr>
</tbody>
</table>

**G**

Uninjected control Arrested KDM4A mRNA injected Arrested Expanded blastocyst

**H**

**legend on next page**
reprogramming barrier, H3K9me3 in the somatic cell genome, can be removed by any member of the KDM4 family demethylases as long as it contains H3K9me3 demethylase activity.

**KDM4A mRNA Injection Significantly Increases the Blastocyst Formation Rate of Human SCNT Embryos**

We next asked whether KDM4A mRNA injection could also help overcome the reprogramming barrier in human SCNT using the optimized SCNT conditions including the use of the histone deacetylase inhibitor Trichostatin A (TSA) (Tachibana et al., 2013). With the future clinical application of KDM4A-assisted SCNT in mind, we used dermal fibroblasts of Age-related Macular Degeneration (AMD) patients as nuclear donors.

To reaffirm the beneficial effect of KDM4A on human SCNT, we chose oocyte donors whose oocytes failed to develop to the expanded blastocyst in our past attempts using the regular procedures (Chung et al., 2014). Following enucleation, a total of 114 MII oocytes collected from four oocyte donors were fused to donor fibroblast cells by HVJ-E (Hemagglutinating virus of Japan envelope). Upon activation, 63 of the reconstructed SCNT oocytes were injected with human KDM4A mRNA, and the rest (51) served as non-injected controls (Figure 2E, Table S4). We monitored the developmental process of these SCNT embryos and found that the two groups featured similar cleavage efficiencies to form two-cell embryos (control: 48/51 = 94.1%, KDM4A: 56/63 = 88.9%) (Table S4). As expected, KDM4A mRNA injection did not show any beneficial effect on the developmental rate of SCNT embryos before ZGA finishes at the end of the eight-cell stage (68.8% versus 71.4%) (Figure 2F and Table S4). However, the beneficial effect became clear at the morula stage (16.7% versus 32.1%) (Figure 2F and Table S4). Strikingly, at day 6, 26.8% (15/56) of the KDM4A-injected embryos had successfully reached the blastocyst stage, while none of the control embryos developed into this stage (Figures 2F and Table S4). After we removed the zona pellucida, the expanded blastocysts were cultured on irradiated mouse embryonic fibroblasts (MEFs) in a conventional ESC derivation medium. Seven out of the eight blastocysts attached to the MEF feeder cells and initiated outgrowth. After five passages, we successfully derived four stable NT-ESC lines, which were designated as NTK (NT assisted by KDM4A)-ESC #6–9, respectively (Figure 3A, also named CHA-NT #6–9). Immunostaining revealed that OCT4, NANOG, SOX2, SSEA-4, and TRA1-60 were all expressed with similar patterns to those of a control human ESC line derived by IVF (Figures 3B, S2A, and S2B). RNA-seq (Figure S2C) revealed that the NTK-ESCs express pluripotency marker genes at levels similar to those of control ESCs (Figure 3C). Pairwise comparison of global transcriptomes revealed a high correlation between NTK-ESCs and control ESCs (Figures 3D and S2D). Hierarchical clustering analyses of transcriptomes revealed that NTK-ESCs are clustered together with control ESCs (Figure 3E). These results suggest that NTK-ESCs are indistinguishable from control ESCs at the molecular level.

We next examined the differentiation capacity of the NTK-ESCs by in vitro differentiation and in vivo teratoma assays. Immunostaining of embryoid bodies (EBs) after 2 weeks of culture revealed that the NTK-ESCs could efficiently give rise to all three germ layer cells (Figures 3F and S2E). Moreover, the NTK-ESCs formed teratomas containing all three germ layer cells within 12 weeks of transplantation (Figures 3G and S2F). These results indicate that the NTK-ESCs are pluripotent.

Karyotyping demonstrated that these NTK-ESCs maintain a normal number of chromosomes and have the same expected pair of sex chromosomes as those of the nuclear donor somatic cells (46, XX for NTK6/7; 46, XY for NTK8; Figures 3H and S3A). Short Tandem Repeat (STR) analysis demonstrated that all of the 16 repeat markers located across the genome showed a perfect match between donor somatic cells and their derivative NTK-ESCs (Figures 3I and S3B). mtDNA sequence analysis revealed that both SNPs of NTK-ESCs matched exactly those of oocyte donors, but not those of nuclear donors (Figures 3J and S3C). Collectively, these results establish the reliability of our SCNT method, and they demonstrate that KDM4A mRNA injection improves SCNT-mediated ESC derivation without compromising pluripotency or genomic stability of the established NTK-ESCs.

**Establishment and Characterization of Human ESCs Derived from KDM4A-Injected SCNT Blastocysts**

We next attempted to derive NT-ESCs from KDM4A-injected SCNT blastocysts. We obtained a total of eight expanded blastocysts from KDM4A-injected SCNT embryos (Figure 3A and Table S4). After we removed the zona pellucida, the expanded blastocysts were cultured on irradiated mouse embryonic fibroblasts (MEFs) in a conventional ESC derivation medium. Seven out of the eight blastocysts attached to the MEF feeder cells and initiated outgrowth. After five passages, we successfully derived four stable NT-ESC lines, which were designated as NTK (NT assisted by KDM4A)-ESC #6–9, respectively (Figure 3A, also named CHA-NT #6–9). Immunostaining revealed that OCT4, NANOG, SOX2, SSEA-4, and TRA1-60 were all expressed with similar patterns to those of a control human ESC line derived by IVF (Figures 3B, S2A, and S2B). RNA-seq (Figure S2C) revealed that the NTK-ESCs express pluripotency marker genes at levels similar to those of control ESCs (Figure 3C). Pairwise comparison of global transcriptomes revealed a high correlation between NTK-ESCs and control ESCs (Figures 3D and S2D). Hierarchical clustering analyses of transcriptomes revealed that NTK-ESCs are clustered together with control ESCs (Figure 3E). These results suggest that NTK-ESCs are indistinguishable from control ESCs at the molecular level.

We next examined the differentiation capacity of the NTK-ESCs by in vitro differentiation and in vivo teratoma assays. Immunostaining of embryoid bodies (EBs) after 2 weeks of culture revealed that the NTK-ESCs could efficiently give rise to all three germ layer cells (Figures 3F and S2E). Moreover, the NTK-ESCs formed teratomas containing all three germ layer cells within 12 weeks of transplantation (Figures 3G and S2F). These results indicate that the NTK-ESCs are pluripotent.

Karyotyping demonstrated that these NTK-ESCs maintain a normal number of chromosomes and have the same expected pair of sex chromosomes as those of the nuclear donor somatic cells (46, XX for NTK6/7; 46, XY for NTK8; Figures 3H and S3A). Short Tandem Repeat (STR) analysis demonstrated that all of the 16 repeat markers located across the genome showed a perfect match between donor somatic cells and their derivative NTK-ESCs (Figures 3I and S3B). mtDNA sequence analysis revealed that both SNPs of NTK-ESCs matched exactly those of oocyte donors, but not those of nuclear donors (Figures 3J and S3C). Collectively, these results establish the reliability of our SCNT method, and they demonstrate that KDM4A mRNA injection improves SCNT-mediated ESC derivation without compromising pluripotency or genomic stability of the established NTK-ESCs.

**Figure 2. Injection of Human KDM4A mRNA Improves Development of Mouse and Human SCNT Embryos**

(A) Schematic illustration of the mouse SCNT procedures.

(B) Representative nuclear images of one-cell stage SCNT embryos stained with anti-H3K9me3 and DAPI at 5 hr after mRNA injection.

(C) KDM4A mRNA injection greatly improves preimplantation development of mouse SCNT embryos. Shown is the percentage of embryos that reached the expanded blastocyst stage, while none of the control embryos developed into this stage (Figures 2F and Table S4).

(D) Representative images of SCNT embryos after 120 hr of culturing in vitro. Scale bar, 100 μm.

(E) Schematic illustration of the human SCNT procedures.

(F) Bar graph showing the average developmental efficiency of human SCNT embryos obtained using oocytes from four different donors during 7 days of in vitro culture. The efficiency was calculated using the number of embryos that reached the two-cell stage. Blast, blastocyst; ExBlast, expanded blastocyst. Developmental rates were statistically analyzed by Fisher’s exact test.

(G) Representative images of SCNT embryos after 7 days of culturing in vitro.

(H) Bar graphs showing the developmental rate of human SCNT embryos derived from each oocyte-donor female. See also Tables S3 and S4.
**Figure 3. Establishment and Characterization of NTK-ESCs from AMD Patients**

(A) Summary of established NT-ESC lines using AMD patient fibroblasts as nuclear donors through KDM4A-assisted SCNT.

(B) Representative phase contrast and immunostaining images of NTK-ESCs. Scale bar, 100 μm.

(C) Bar graphs showing expression levels of pluripotency-specific and fibroblast-specific genes based on RNA-seq data.

(D) ESC15 vs. NTK6 

(E) Expression level (FPKM) 

(F) NTK6

(G) NTK6

(H) NTK6 (XX)

(I) Fibroblast | NTK6 | Oocyte donor

<table>
<thead>
<tr>
<th>AMEL</th>
<th>X</th>
<th>X</th>
<th>X</th>
<th>X</th>
<th>X</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>D8S1179</td>
<td>12</td>
<td>13</td>
<td>12</td>
<td>13</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>D21511</td>
<td>12</td>
<td>13</td>
<td>12</td>
<td>13</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>D75820</td>
<td>11</td>
<td>12</td>
<td>11</td>
<td>12</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>CSF1PO</td>
<td>19</td>
<td>13</td>
<td>10</td>
<td>13</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td>D8S1358</td>
<td>15</td>
<td>16</td>
<td>15</td>
<td>16</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>TH01</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>D13S317</td>
<td>8</td>
<td>11</td>
<td>8</td>
<td>11</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>D18S51</td>
<td>11</td>
<td>13</td>
<td>11</td>
<td>13</td>
<td>9</td>
<td>11</td>
</tr>
<tr>
<td>D5S818</td>
<td>11</td>
<td>13</td>
<td>11</td>
<td>13</td>
<td>9</td>
<td>11</td>
</tr>
<tr>
<td>TPOX</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>D18S51</td>
<td>14</td>
<td>15</td>
<td>14</td>
<td>15</td>
<td>13</td>
<td>16</td>
</tr>
<tr>
<td>DXS219</td>
<td>16</td>
<td>14</td>
<td>16</td>
<td>14</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>FGA</td>
<td>16</td>
<td>14</td>
<td>16</td>
<td>14</td>
<td>16</td>
<td>16</td>
</tr>
</tbody>
</table>

(legend continued on next page)
in donor somatic cell genome indeed functions as a barrier for ZGA in human SCNT embryos, as is the case in mouse. To determine to what extent the injection of KDM4A mRNAs could overcome ZGA defects in the SCNT embryos, we performed RNA-seq of eight-cell SCNT embryos with or without KDM4A injection. Comparative transcriptome analyses indicated that as much as 50% (158) of the 318 RRRs were markedly upregulated by KDM4A mRNA injection (Figure 4A, FC > 2), indicating that erasure of H3K9me3 can at least partly facilitate ZGA in SCNT embryos.

Figure 4. Partial Restoration of Transcription upon KDM4A mRNA Injection in SCNT Eight-Cell Embryos
(A) Heatmap comparing transcription levels of the 318 RRRs at the late eight-cell stage. The expression levels of 158 out of the 318 RRRs are markedly (FC > 2) increased in response to KDM4A mRNA injection. (B) Gene ontology analysis of the 206 KDM4A-responsive genes (FC > 2). (C) Bar graphs and genome browser view of transcription levels of two representative KDM4A-responsive genes, UBTFL1 and THOC5, in IVF or SCNT (with or without KDM4A mRNA injection) eight-cell embryos. See also Table S5.

To identify candidate genes that might help explain the improved development of KDM4A-injected SCNT embryos, we focused our analysis on genes (instead of repeats or non-coding regions). We identified 206 genes (Table S5) whose expression was significantly upregulated by KDM4A injection (FPKM > 5, FC > 2). Gene ontology analysis revealed that these genes were enriched for transcriptional regulation, ribosomal biogenesis, and RNA processing (Figure 4B), suggesting that dysregulation of these developmentally important machineries might be a cause of developmental arrest of SCNT embryos. Although the function of the majority of the 206 genes in preimplantation development is currently unknown, two of them, UBTFL1 and THOC5 (Figure 4C), are known to be required for normal preimplantation development in mice (Wang et al., 2013; Yamada et al., 2010). Therefore, defective activation of these genes is at least partly responsible for the poor development of human SCNT embryos.

DISCUSSION
After decades of efforts, human NT-ESCs were finally derived recently (Chung et al., 2014; Tachibana et al., 2013; Yamada et al., 2014). These advances were mainly due to optimization of SCNT derivation conditions. However, the intrinsic defects
in epigenetic reprogramming that cause the developmental arrest of human SCNT embryos have not been identified. In this study, we demonstrate that similar to mouse, H3K9me3 in somatic cell genome presents a barrier for human SCNT reprogramming. Removal of this barrier by overexpressing the H3K9me3 demethylase KDM4A facilitates transcriptional reprogramming at ZGA, thereby allowing human SCNT embryos to develop more efficiently to generate blastocysts, from which we successfully established multiple AMD-patient-specific NT-ESC lines without compromising genomic stability or pluripotency. Our study thus not only demonstrates that H3K9me3 serves as a general reprogramming barrier, but it also establishes a practical approach for improving cloning efficiency.

It has been well known that the ability of human oocytes to support SCNT embryo development varies greatly among oocyte donors. Indeed, human NT-ESCs can be derived only when high-quality oocytes donated by a small group of females support SCNT embryo development varies greatly among species. It is therefore possible that some of the human oocytes that we used in our experiments could not support blastocyst formation even by IVF.

In summary, we have established an improved KDM4-assisted SCNT method. Using this method, we derived blastocysts from adult AMD patient cells and subsequently established multiple NTK-ESCs with genomes identical to those of donor patients. This provides unique and important cell sources for understanding AMD as well as for therapeutic drug screening for AMD treatments. Given that the same strategy can be applied to the studies of other human diseases, we anticipate that our study will have a general impact on human therapeutics. Additionally, since SCNT allows replacement of somatic cell mitochondria with that of the recipient oocyte, as we have demonstrated in this study (Figures 3H–3J and S3), it provides an opportunity to treat mtDNA-related diseases. Indeed, a recent study demonstrated that a metabolic syndrome phenotype caused by mtDNA mutation can be corrected by replacing mtDNA through SCNT (Ma et al., 2015). Thus, our KDM4-assisted SCNT method should be useful for mtDNA-replacement therapies.

EXPERIMENTAL PROCEDURES

Human SCNT Procedure and KDM4A mRNA Injection

All MII stage oocytes with distinctive first polar bodies were enucleated under an inverted microscope equipped with a Poloscope (Oisight, Cambridge Research & Instrumentation). The enucleation and nuclear donor cell fusion were carried out in the presence of caffeine (1.25 mM). For enucleation, oocytes were pre-incubated in Global HTF medium with HEPES (Life Global) containing 0.5 μg/ml cytochalasin B and caffeine (1.25 mM) for 5 min. Then, the spindle complex was removed using a PIEZO actuator (Primentech). Dermal fibroblasts cells resuspended in a drop containing HV-J-E extract (Cosmo Bio) were inserted into the perivitelline space of the enucleated oocytes. The reconstructed oocytes were kept in the manipulation medium containing caffeine (1.25 mM) until cell fusion was confirmed, and then the reconstructed oocytes were transferred into Global medium (10% SPS) and incubated for 1–1.5 hr before activation. Activation was carried out by the application of electro-pulses (2× 50 μs DC pulses, 2.7 kV/cm) in 0.25 M d-sorbitol buffer and 6-DMA (2 mM, 4 hr) as previously described (Tachibana et al., 2013). The activated embryos were transferred to Global 10% SPS medium supplemented with TSA (10 nM, Sigma) for 12 hr, and then the embryos were transferred to Global 10% FBS without TSA and cultured for up to 7 days in an incubator with an atmosphere of 6% CO2/5% O2/89% N2 at 37° C. The culture medium was changed on day 3.

For mRNA injection, the activated SCNT embryos were washed and cultured in Global 10% SPS for 1 hr before the KDM4A mRNA injection. Approximately 10 pl of KDM4A mRNA was injected into the SCNT embryos at 5 hr after activation in HEPES-HTF 10% SPS medium using a PIEZO actuator as described previously (Matoba et al., 2014). More details on donor cell preparation, mRNA preparation, RNA-seq, and other procedures can be found in the Supplemental Experimental Procedures.

Identification of Human RRRs

A sliding window (size 20 kb, step size 10 kb) was used to assess the genome-wide expression level of four-cell and eight-cell human embryos. For each window, the expression level was quantified with normalized RPM (reads per millions of uniquely mapped reads). The significantly activated regions in eight-cell relative to four-cell IVF embryos were identified with stringent criteria (FC > 5, RPM > 5 in eight-cell IVF embryos), and the overlapping regions were merged. These activated regions were classified into three groups based on their expression differences in human SCNT and IVF eight-cell embryos.

ACCESSION NUMBERS

The accession number of the RNA-seq datasets reported in this paper is GEO: GSE73362.
SUPPLEMENTAL INFORMATION

Supplemental Information for this article includes three figures, five tables, and Supplemental Experimental Procedures and can be found with this article online at http://dx.doi.org/10.1016/j.stem.2015.10.001.

AUTHOR CONTRIBUTIONS


ACKNOWLEDGMENTS

We thank Dr. Luis Tuesta for critical reading of the manuscript; Drs. Sungwook Hong and Yumie Lee for oocyte preparations and donor recruitments, respectively; and Dr. Young Ho Choi for technical help in SCNT. This project is supported by HHMI (to Y.Z.) and the Bio & Medical Technology Development Program (2012M3A9C6049723 and 2015M3A9C6028961) of NRF and MSIP of Republic of Korea (to D.R.L). This project is also partially supported by Cha Medical Foundation in Republic of Korea (to D.R.L). S.M. is supported by a postdoctoral fellowship from the Japan Society for the Promotion of Science (JSPS). W.J. is supported by a Juvenile Diabetes Research Foundation post-doctoral fellowship (3-2012-293). Y.Z. is an Investigator of the Howard Hughes Medical Institute.

Received: July 28, 2015
Revised: September 4, 2015
Accepted: October 3, 2015
Published: October 29, 2015

REFERENCES


